Daniel Rosenbaum

Daniel Rosenbaum

Auto-generated profile, based on publicly available information

Daniel Rosenbaum

University Health Network

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2019 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
TAThomas Anderson
Thomas Anderson
RPRotem Petranker
Rotem Petranker
DRDaniel Rosenbaum
Daniel Rosenbaum
CWCory R. Weissman
Cory R. Weissman
LDLe-Anh Dinh-Williams
Le-Anh Dinh-Williams
NFNorman Farb
Norman Farb

10 July 2019 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
TAThomas Anderson
Thomas Anderson
RPRotem Petranker
Rotem Petranker
ACAdam Christopher
Adam Christopher
DRDaniel Rosenbaum
Daniel Rosenbaum
CWCory R. Weissman
Cory R. Weissman
EHEmma Hapke
Emma Hapke
Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. In the present study, we develop a codebook of microdosing benefits and challenges (MDBC) based on the qualitative reports of a real-world sample of 278 microdosers. We describe novel findings, both in terms of beneficial outcomes, such as improved mood (26.6%) and focus (14.8%), and in terms of challenging outcomes, such as physiological discomfort (18.0%) and increased anxiety (6.7%). We also show parallels between benefits and drawbacks and discuss the implications of these results. We probe for substance-dependent differences, finding that psilocybin-only users report the benefits of microdosing were more important than other users report. These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research. The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated. Microdosing research complements the full-dose literature as clinical treatments are developed and neuropharmacological mechanisms are sought. This framework aims to inform researchers and clinicians as experimental microdosing research begins in earnest in the years to come.

28 February 2020 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
DRDaniel Rosenbaum
Daniel Rosenbaum
CWCory Weissman
Cory Weissman
TAThomas Anderson
Thomas Anderson
RPRotem Petranker
Rotem Petranker
LDLe-Anh Dinh-Williams
Le-Anh Dinh-Williams
EHEmma Hapke
Emma Hapke
Rationale: Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. Objectives: To examine the practices and demographics of a population of psychedelic microdosers – including their psychiatric diagnoses, prescription medications, and recreational substance use patterns – to develop a foundation on which to conduct future clinical research. Methods: Participants ( n = 909; Mage = 26.9, SD = 8.6; male = 83.2%; White/European = 79.1%) recruited primarily from the online forum Reddit completed an anonymous online survey. Respondents who reported using LSD, psilocybin, or both for microdosing were grouped and compared with non-microdosing respondents using exploratory odds ratio testing on demographic variables, rates of psychiatric diagnoses, and past-year recreational substance use. Results: Of microdosers, most reported using LSD (59.3%; Mdose = 13 mcg, or 11.3% of one tab) or psilocybin (25.9%; Mdose = 0.3 g of dried psilocybin mushrooms) on a one-day-on, two-days-off schedule. Compared with non-microdosers, microdosers were significantly less likely to report a history of substance use disorders (SUDs; OR = 0.17 (95% CI: 0.05–0.56)) or anxiety disorders (OR = 0.61 (95% CI: 0.41–0.91)). Microdosers were also more likely to report recent recreational substance use compared with non-microdosers (OR = 5.2 (95% CI: 2.7–10.8)). Conclusions: Well-designed randomized controlled trials are needed to evaluate the safety and tolerability of this practice in clinical populations and to test claims about potential benefits.

1 August 2019 in Current Oncology
Verified
Journal Article
Open access
DRD. Rosenbaum
D. Rosenbaum
ABA.B. Boyle
A.B. Boyle
ARA.M. Rosenblum
A.M. Rosenblum
SZS. Ziai
S. Ziai
MCM.R. Chasen
M.R. Chasen
In recent years, there has been renewed scientific interest in, and associated media coverage of, psychedelics.

3 April 2023 in AJOB Neuroscience
Verified
Journal Article
Closed access
DRDaniel Rosenbaum
Daniel Rosenbaum
MCMatthew Cho
Matthew Cho
ESEvan Schneider
Evan Schneider
SHSarah Hales
Sarah Hales
DBDaniel Z. Buchman
Daniel Z. Buchman
Peterson et al. (2023) identify important ethical issues that are relevant to psychedelic therapy and research in various clinical populations and contexts. This is certainly the case in palliative...

1 March 2024 in Public Health Ethics
Verified
Journal Article
Open access
PDF file
DBDaniel Buchman
Daniel Buchman
DRDaniel Rosenbaum
Daniel Rosenbaum
The nascent for-profit psychedelic industry has begun to engage in corporate practices like funding scientific research and research programs. There is substantial evidence that such practices from other industries like tobacco, alcohol, pharmaceuticals and food create conflicts of interest and can negatively influence population health. However, in a context of funding pressures, low publicly funded success rates and precarious academic labor, there is limited ethics guidance for researchers working at the intersection of clinical practice and population health as to how they should approach potential financial sponsorship from for-profit entities, such as the psychedelic industry. This article reports on a reflective exercise among a group of clinician scientists working in psychedelic science, where we applied Adams’ (2016) PERIL (Purpose, Extent, Relevant harm, Identifiers, Link) ethical decision-making framework to a fictionalized case of corporate psychedelic financial sponsorship. Our analysis suggests financial relationships with the corporate psychedelic sector may create varying degrees of risk to a research program’s purpose, autonomy and integrity. We argue that the commercial determinants of health provide a useful framework for understanding the ethics of industry-healthcare entanglements and can provide an important population health ethics lens to examine nascent industries such as psychedelics, and work toward potential solutions.